PLTR — Palantir Technologies Inc.

Sentiment is constructive on the business and defensive on the price. The Q2 2026 print filed 2026-08-04 beat decisively (revenue $1.94B vs ~$1.81B consensus, EPS $0.41 vs $0.34 expected) and management raised FY2026 revenue guidance to ~$8.15B with adjusted FCF of $4.5-4.7B, triggering a ~50% August rally and prompting DA Davidson to lift its target from $200 to $250. But the tape has cooled: as of 2026-09-13 the stock was -4.07% on the week, -2.23% on the month, and RSI sat at 49.16, with the FMP analyst consensus at 13 buy / 10 hold / 3 sell and an average target of $180.50 (recent average $183.33) - only modestly above the $167.23 price. The market loves this company; it is no longer obviously underpaying for it.

Unambiguously accelerating, not a blip. Quarterly revenue ran $558M (Q3 2023) to $1,935M (Q2 2026), and YoY growth has stepped up six consecutive quarters: +39% (Q1 2025), +48% (Q2 2025), +63% (Q3 2025), +70% (Q4 2025), +85% (Q1 2026), +93% (Q2 2026). Sequential growth has held at +16% to +19% per quarter since Q3 2025, so this is compounding rather than easy comps. GAAP operating margin expanded from 1.3% (Q4 2024) to 26.8%, 33.3%, 40.9%, 46.2% and 47.1% in the five quarters since, with R&D up only 43% YoY ($135M to $193M) against 93% revenue growth - real operating leverage, not accounting noise. Diluted EPS went $0.13 (Q2 2025) to $0.41 (Q2 2026) and quarterly FCF went $532M to $1,202M. Two caveats: GAAP net income ($1,062M in Q2 2026) is running above operating income ($912M), so interest income on a growing cash pile and tax items are flattering the bottom line; and the growth is concentrated in US commercial (+149% YoY per the research brief), which cuts both ways. Structural trend: up and to the right; the biggest long-run risk is the law of large numbers, not a reversal.

Expensive on every absolute measure as of 2026-09-13: 132.7x TTM EPS of $1.259, 104x the next-FY consensus EPS of $1.602, 62.4x TTM sales (~47x the ~$8.19B forward revenue estimate), 41x book, 138x EV/EBITDA, and a TTM FCF yield of just ~0.9% (1.2% on the $4.6B FY2026 FCF guide midpoint). The company's own-history comparison (5-year average P/E of 264.5, average P/S of 39.95) makes it look tame, but that average spans years when Palantir had a fraction of today's revenue and no GAAP profits - it is a weak anchor. P/S at 62x TTM is well above, not in line with, its 5-year average. The PEG of 0.471 is a mechanical artifact of a ~280% trailing EPS jump and should be ignored entirely. Verdict: rich. There is no margin of safety at this price; you are paying for a decade of above-market compounding up front.

The earnings print is not the risk - the multiple is. At ~104x forward EPS, a routine beat-and-raise for FY2027 (even to 45-50% growth) is already capitalized into the price, so positive results may not move the stock much, while a re-rate of the multiple alone can. Holding a plausible FY2027 EPS near $2.30, 100x forward earnings is a ~$230 stock and 60x is a ~$138 stock - the same earnings produce a 40%+ swing. That asymmetry means entry price and position size matter more here than the next two quarters of results, and it argues for buying weakness rather than momentum. The mirror image: Palantir has out-run the growth its multiple implied for three straight years, so shorting 'expensive' has been a losing trade - the discipline is not to fight the trend but to size for a 30-40% air pocket.

Neutral-to-constructive consolidation as of 2026-09-13: RSI(14) at 49.16 (dead center), price 4.74% below its 20-day SMA but 8.64% above its 50-day and 10.37% above its 200-day, with -4.07% over one week and -2.23% over one month against +30.66% over three months and +10.79% over six months. The August parabola is being digested inside an intact uptrend. This is neither an oversold entry nor a breakout; the actionable levels are roughly $155-165 (the 50-day area and the post-earnings gap), where a pullback would be a legitimate trend test, and a decisive close below the 50-day would be the first real warning since spring. Absent that, expect range-bound chop between roughly $160 and $185 until the Q3 print.

• Rates and duration: a ~47x forward sales multiple makes most of the valuation a terminal-value bet, so it is acutely sensitive to real yields and any renewed upward move in the 10-year Treasury.
• Enterprise AI 'sovereignty' shift: corporates moving away from generic cloud APIs toward on-prem/sovereign, multi-model deployments is a direct tailwind for Foundry and AIP - but it also invites hyperscalers (Microsoft, Google, AWS) and model vendors to bundle competing data/AI stacks.
• US defense/intelligence budget cycle: government revenue is tied to appropriations and contract award timing, so continuing resolutions, budget impasses or a shift in spending priorities create lumpy quarters.
• AI-sector concentration and rotation: the S&P's returns are heavily concentrated in AI beneficiaries, so a sector-wide de-rating drags PLTR with it regardless of company-specific execution (beta of 1.62 amplifies this).
• Data-privacy, export-control and procurement regulation across the US, EU and allied governments affects cross-border deployments and the pace of sovereign AI contract signings.

• Q3 2026 earnings, expected early November 2026 - the primary test of whether 80%+ top-line growth and 47%+ operating margins are sustainable or were a peak quarter.
• US commercial/AIP pipeline conversion into large enterprise contracts following AIPCon 11; US commercial grew 149% YoY in Q2 2026 and is the swing factor in the growth story.
• Execution and expansion of the Nvidia partnership (Nemotron open models inside Foundry/AIP, on-premise and sovereign deployments) and the Nebius infrastructure agreement, which broaden the addressable deployment footprint.
• Further guidance raises, including upside to the $4.5-4.7B FY2026 adjusted FCF range, and any new allied-government sovereign AI awards.
• Sell-side target revisions - the range is already extreme ($80 low to $250-255 high), so new initiation or upgrade/downgrade flow can move the stock on sentiment alone.

• Valuation with zero cushion: 104x forward EPS, ~47x forward sales, 138x EV/EBITDA, 0.9% TTM FCF yield. A re-rate to merely 'expensive' (60-70x forward EPS) is a 30-45% drawdown with no change in the business.
• Deceleration asymmetry: growth is 93% YoY today and mathematically must slow; a guide toward 40-50% growth could be read as a broken thesis even though it would still be elite for software.
• Revenue concentration in US government/defense and a limited number of very large contracts, where award timing and renewal cycles create quarter-to-quarter volatility.
• Stock-based compensation and share creep - net income of $1,062M on diluted EPS of $0.41 implies roughly 2.6B diluted shares versus a market-cap-implied ~2.3B shares outstanding, so dilution is a persistent tax on per-share value.
• Competitive encroachment from hyperscalers and data-platform vendors (Databricks, Snowflake, Microsoft Fabric) moving toward the same semantic-layer/workflow territory, plus any open-source substitution pressure on pricing.
• Crowded positioning and high beta (1.62) after a ~50% single-month move - the shareholder base is momentum-heavy and quick to exit on any macro risk-off episode.

This is a genuinely elite business at a price that already assumes near-flawless execution for a decade. The fundamentals are exceptional and improving - 93% YoY revenue growth, 47% GAAP operating margin, $1.2B quarterly FCF, zero long-term debt, $7.2x current ratio - and the deterministic score's 'Strong Fundamentals' band is deserved. But at 104x forward EPS and a 0.9-1.2% FCF yield, my own probability-weighted DCF lands around $135, roughly 20% below the 2026-09-13 price of $167.23, and the framework's own valuation overlay is at best neutral. Own it if you have a decade-long horizon and can stomach a 35% drawdown; do not buy it here expecting a margin of safety, and prefer adding on a test of the 50-day rather than on strength.

Probability-weighted two-stage FCF DCF as of 2026-09-13, starting from the FY2026 adjusted FCF guidance midpoint of $4.6B: bear case (25%) assumes FCF growth decays to ~30%/22%/16% with a 11.5% discount rate and 3% terminal growth (~$88/share); base case (50%) assumes 45%/35%/28%/23%/19% for 2027-2031, then 12%, a 10.5% discount rate and 3.5% terminal (~$113/share); bull case (25%) assumes 50%+ growth sustained far longer on a 9.5% discount rate and 4% terminal (~$225/share). Probability-weighting those three (0.25 x 88 + 0.50 x 113 + 0.25 x 225) yields ~$135, i.e. roughly 20% below the $167.23 price, with net cash of ~$2B added and ~2.30B shares used for consistency with the market cap.